Teriflunomide [163451-81-8]
Katalog-Nummer HY-15405-100mg
Size : 100mg
Marke : MedChemExpress
Teriflunomide is the active metabolite of leflunomide, an approved therapy for rheumatoid arthritis. It inhibits pyrimidine synthesis and therefore potently decreases T cell and B cell proliferation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
Teriflunomide Chemische Struktur
CAS. Nr. : 163451-81-8
This product is a controlled substance and not for sale in your territory.
Based on 11 publication(s) in Google Scholar
Other Forms of Teriflunomide:
- (E/Z)-Teriflunomide Angebot einholen
- Teriflunomide (Standard) Angebot einholen
Beschreibung |
Teriflunomide is the active metabolite of leflunomide, an approved therapy for rheumatoid arthritis. It inhibits pyrimidine synthesis and therefore potently decreases T cell and B cell proliferation. |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
In Vitro |
Teriflunomide primarily acts as an inhibitor of dihydroorotate dehydrogenase (DHODH), a key mitochondrial enzyme involved in the de novo synthesis of pyrimidines in rapidly proliferating cells. By reducing the activity of high-avidity proliferating T lymphocytes and B lymphocytes, teriflunomide likely attenuates the inflammatory response to autoantigens in MS. Thus, teriflunomide can be considered a cytostatic rather than a cytotoxic drug to leukocytes[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
In Vivo |
Teriflunomide has demonstrated beneficial effects in two independent animal models of demyelinating disease. In the dark agouti rat model of experimental autoimmune encephalitis (EAE), teriflunomide administration results in clinical, histopathological, and electrophysiological evidence of efficacy both as a prophylactic and therapeutic agent. Similarly, in the female Lewis rat model of EAE, teriflunomide administration results in beneficial prophylactic and therapeutic clinical effects, with a delay in disease onset and symptom severity[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
Klinische Studie |
|
||||||||||||
Molekulargewicht |
270.21 |
||||||||||||
Formel |
C12H9F3N2O2 |
||||||||||||
CAS. Nr. |
163451-81-8 |
||||||||||||
Appearance |
Solid |
||||||||||||
Color |
White to off-white |
||||||||||||
SMILES |
C/C(O)=C(C#N)/C(NC1=CC=C(C(F)(F)F)C=C1)=O |
||||||||||||
Versand | Room temperature in continental US; may vary elsewhere. |
||||||||||||
Speicherung |
|
||||||||||||
Lösungsmittel & Löslichkeit |
In Vitro:
DMSO : 33.33 mg/mL (123.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||
Reinheit & Dokumentation |
Purity: 99.94% |
||||||||||||
Verweise |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 3.7008 mL | 18.5041 mL | 37.0083 mL | 92.5206 mL |
5 mM | 0.7402 mL | 3.7008 mL | 7.4017 mL | 18.5041 mL | |
10 mM | 0.3701 mL | 1.8504 mL | 3.7008 mL | 9.2521 mL | |
15 mM | 0.2467 mL | 1.2336 mL | 2.4672 mL | 6.1680 mL | |
20 mM | 0.1850 mL | 0.9252 mL | 1.8504 mL | 4.6260 mL | |
25 mM | 0.1480 mL | 0.7402 mL | 1.4803 mL | 3.7008 mL | |
30 mM | 0.1234 mL | 0.6168 mL | 1.2336 mL | 3.0840 mL | |
40 mM | 0.0925 mL | 0.4626 mL | 0.9252 mL | 2.3130 mL | |
50 mM | 0.0740 mL | 0.3701 mL | 0.7402 mL | 1.8504 mL | |
60 mM | 0.0617 mL | 0.3084 mL | 0.6168 mL | 1.5420 mL | |
80 mM | 0.0463 mL | 0.2313 mL | 0.4626 mL | 1.1565 mL | |
100 mM | 0.0370 mL | 0.1850 mL | 0.3701 mL | 0.9252 mL |
Teriflunomide Related Classifications
- Metabolic Enzyme/Protease
- Drug Metabolite
-
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Keywords:
Teriflunomide163451-81-8A77 1726Drug MetaboliteInhibitorinhibitorinhibit